Association between perioperative statin–ezetimibe therapy and reoperation following arthroscopic rotator cuff repair: A TriNetX database study
- 1Department of Orthopaedics & Sports Medicine, University of Cincinnati, Cincinnati, USA
Abstract
Background: Hyperlipidemia (HLD) impairs tendon healing and is associated with increased revision risk following arthroscopic rotator cuff repair (ARCR). While statins may partially mitigate this effect, residual dyslipidemia may impair healing. Ezetimibe, through inhibition of intestinal cholesterol absorption, has demonstrated favorable effects on tendon healing in preclinical studies.
Objectives: This study evaluated whether perioperative statin–ezetimibe therapy is associated with improved postoperative outcomes following ARCR compared with statin monotherapy and patients without HLD.
Methods: A retrospective cohort study was conducted using the TriNetX Research Network. Adult patients undergoing ARCR were stratified into three cohorts based on HLD status and perioperative (± 6 months) lipid-lowering therapy: (1) documented HLD treated with statin–ezetimibe prescriptions, (2) patients without documented HLD or lipid-lowering therapy prescriptions, and (3) documented HLD treated with statin monotherapy prescriptions. Primary comparisons were predefined between cohort 1 and cohorts 2 and 3. Propensity score matching (1:1) adjusted for demographics and comorbidities. Tear size and presence of fatty atrophy and fatty infiltration were not adjusted for. Outcomes occurring within 5 years included revision rotator cuff repair (RCR), conversion to shoulder arthroplasty, and secondary shoulder arthroscopy.
Results: After matching, 1,066 patients were included in cohorts 1 and 2 and 1,114 patients in cohorts 1 and 3. Compared with patients without HLD, statin–ezetimibe therapy demonstrated similar rates of revision RCR (5.4% vs. 6.4%; RR 0.853; p = 0.358), conversion to shoulder arthroplasty (RR 1.227; p = 0.470), and secondary arthroscopy (RR 0.846; p = 0.260). Compared with statin monotherapy, statin–ezetimibe therapy was associated with lower rates of revision RCR (5.6% vs. 8.0%; RR 0.697; p = 0.023) and secondary shoulder arthroscopy (7.3% vs. 9.6%; RR 0.757; p = 0.048), while arthroplasty rates remained similar (RR 1.261; p = 0.400).
Conclusion: Among patients with HLD undergoing ARCR, perioperative statin–ezetimibe therapy was associated with lower reoperation rates compared with statin monotherapy and postoperative outcomes comparable to patients without HLD. These findings support further investigation of intensified lipid-lowering therapy, while accounting for tear size and fatty infiltration.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s40199-026-00678-y.
Related
- Association of a multimodal perioperative nutritional/ERAS care pathway with postoperative infectious complications following radical hysterectomy for cervical cancer: a retrospective nonconcurrent cohort study
- Racial differences in reoperation rates following dacryocystorhinostomy
- Reoperation and Complication Rates Following Percutaneous Bone Graft and Headless Screw Fixation for Scaphoid Non-union: A 10-Year, Single-Centre Experience
- A Comparative Study of Functional Outcomes Following Arthroscopic Anterior Cruciate Ligament Reconstruction Using Hamstring Tendon versus Peroneus Longus Tendon Autograft
- Clinicopathological and Perioperative Factors Associated with Overall Survival and 90-Day Mortality Following Esophagectomy for Esophageal Cancer
BibTeX
@article{mahatme2026association,
title = {{Association between perioperative statin–ezetimibe therapy and reoperation following arthroscopic rotator cuff repair: A TriNetX database study}},
author = {Ronak Mahatme and Anish Gangavaram and Nishanth Muthusamy and Shawn Moore and Thomas Nayak and Kasey Shao and Brian Grawe and David Bernholt},
journal = {DARU Journal of Pharmaceutical Sciences},
year = {2026},
month = oct,
doi = {10.1007/s40199-026-00678-y},
url = {https://doi.org/10.1007/s40199-026-00678-y},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Association between perioperative statin–ezetimibe therapy and reoperation following arthroscopic rotator cuff repair: A TriNetX database study
AU - Ronak Mahatme
AU - Anish Gangavaram
AU - Nishanth Muthusamy
AU - Shawn Moore
AU - Thomas Nayak
AU - Kasey Shao
AU - Brian Grawe
AU - David Bernholt
PY - 2026
DA - 2026/10/25
JO - DARU Journal of Pharmaceutical Sciences
DO - 10.1007/s40199-026-00678-y
UR - https://doi.org/10.1007/s40199-026-00678-y
AB - Background: Hyperlipidemia (HLD) impairs tendon healing and is associated with increased revision risk following arthroscopic rotator cuff repair (ARCR). While statins may partially mitigate this effect, residual dyslipidemia may impair healing. Ezetimibe, through inhibition of intestinal cholesterol absorption, has demonstrated favorable effects on tendon healing in preclinical studies. Objectives: This study evaluated whether perioperative statin–ezetimibe therapy is associated with improved postoperative outcomes following ARCR compared with statin monotherapy and patients without HLD. Methods: A retrospective cohort study was conducted using the TriNetX Research Network. Adult patients undergoing ARCR were stratified into three cohorts based on HLD status and perioperative (± 6 months) lipid-lowering therapy: (1) documented HLD treated with statin–ezetimibe prescriptions, (2) patients without documented HLD or lipid-lowering therapy prescriptions, and (3) documented HLD treated with statin monotherapy prescriptions. Primary comparisons were predefined between cohort 1 and cohorts 2 and 3. Propensity score matching (1:1) adjusted for demographics and comorbidities. Tear size and presence of fatty atrophy and fatty infiltration were not adjusted for. Outcomes occurring within 5 years included revision rotator cuff repair (RCR), conversion to shoulder arthroplasty, and secondary shoulder arthroscopy. Results: After matching, 1,066 patients were included in cohorts 1 and 2 and 1,114 patients in cohorts 1 and 3. Compared with patients without HLD, statin–ezetimibe therapy demonstrated similar rates of revision RCR (5.4% vs. 6.4%; RR 0.853; p = 0.358), conversion to shoulder arthroplasty (RR 1.227; p = 0.470), and secondary arthroscopy (RR 0.846; p = 0.260). Compared with statin monotherapy, statin–ezetimibe therapy was associated with lower rates of revision RCR (5.6% vs. 8.0%; RR 0.697; p = 0.023) and secondary shoulder arthroscopy (7.3% vs. 9.6%; RR 0.757; p = 0.048), while arthroplasty rates remained similar (RR 1.261; p = 0.400). Conclusion: Among patients with HLD undergoing ARCR, perioperative statin–ezetimibe therapy was associated with lower reoperation rates compared with statin monotherapy and postoperative outcomes comparable to patients without HLD. These findings support further investigation of intensified lipid-lowering therapy, while accounting for tear size and fatty infiltration. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s40199-026-00678-y.
SN - 1560-8115
SN - 2008-2231
ER -